Post a Free Blog

Submit A Press Release

Thursday, March 28, 2024
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Truck Series (TRUCK)
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
-- Advertisement --spot_img
HomeBusinessProthena Corporation’s Q2 Earnings Review

Prothena Corporation’s Q2 Earnings Review


Prothena Corporation (NASDAQ:PRTA) reported its Q2 results, with $1.3 million in collaboration revenue, $44.5 million in OpEx, and $510.1 million in cash.
The company reiterated its prior full-year financial guidance and expects net cash use for operations and investing activities to be in the range of $120-132 million.
Oppenheimer analysts said they remain encouraged by the company’s unique approach with an emphasis on epitope and expertise in understanding misfolded proteins as differentiating. Near term, the analysts expect PRX005 Ph1 top-line data and PRX012 to start the Ph1 MAD study in 2022.

Subscribe to get Latest News Updates

Latest News Articles

You may like more
more

Bloom Energy’s Price Target Cut at Susquehanna

Susquehanna analysts adjusted their price target for Bloom Energy...

Nio Shares Drops 6 percent Following Slashed Q1 Delivery Outlook

NIO (NYSE:NIO) shares fell more than 6% intra-day today...

nCino Shares Jump 19 percent Following Q4 Earnings

nCino (NASDAQ:NCNO) shares surged more than 19% intra-day today...

Tesla’s Price Target Cut at Citi Ahead of Q1 Deliveries

Citi analysts revised Tesla’s (NASDAQ:TSLA) price target down to...